- Home
- ACIC vs KURA Comparison
ACIC vs KURA Comparison
Compare ACIC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- KURA
- Stock Information
- Founded
- ACIC 1999
- KURA 2014
- Country
- ACIC United States
- KURA United States
- Employees
- ACIC N/A
- KURA N/A
- Industry
- ACIC Property-Casualty Insurers
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACIC Finance
- KURA Health Care
- Exchange
- ACIC Nasdaq
- KURA Nasdaq
- Market Cap
- ACIC 556.0M
- KURA 561.9M
- IPO Year
- ACIC N/A
- KURA N/A
- Fundamental
- Price
- ACIC $10.24
- KURA $6.25
- Analyst Decision
- ACIC Buy
- KURA Strong Buy
- Analyst Count
- ACIC 1
- KURA 12
- Target Price
- ACIC $16.00
- KURA $24.50
- AVG Volume (30 Days)
- ACIC 144.2K
- KURA 1.3M
- Earning Date
- ACIC 08-06-2025
- KURA 08-07-2025
- Dividend Yield
- ACIC 4.89%
- KURA N/A
- EPS Growth
- ACIC 3.21
- KURA N/A
- EPS
- ACIC 1.49
- KURA N/A
- Revenue
- ACIC $302,261,000.00
- KURA $67,991,000.00
- Revenue This Year
- ACIC N/A
- KURA $125.04
- Revenue Next Year
- ACIC $37.63
- KURA $83.75
- P/E Ratio
- ACIC $6.85
- KURA N/A
- Revenue Growth
- ACIC 23.92
- KURA N/A
- 52 Week Low
- ACIC $8.82
- KURA $5.41
- 52 Week High
- ACIC $15.08
- KURA $21.57
- Technical
- Relative Strength Index (RSI)
- ACIC 37.80
- KURA 44.86
- Support Level
- ACIC $9.97
- KURA $6.15
- Resistance Level
- ACIC $10.97
- KURA $6.59
- Average True Range (ATR)
- ACIC 0.24
- KURA 0.30
- MACD
- ACIC -0.06
- KURA -0.04
- Stochastic Oscillator
- ACIC 25.00
- KURA 17.73
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.